Mana Capital Acquisition Corp.
MAAQW
NASDAQ Global Market0.20
USD
+0.02
- -
CIK
0001870144
Return %
Stock
S&P500
1Y
33.27
26.53
3Y
-39.41
76.60
5Y
-39.41
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 8 The Green Dover DE United States of America 19901
- IPO Date
- Jan 14, 2022
- CIK
- 0001870144
- Similar Companies
- Business
- Mana Capital Acquisition Corp. (MAAQW) operates as a special purpose acquisition company, or blank check company, focused on effecting mergers, share exchanges, asset acquisitions, share purchases, recapitalizations, reorganizations, or other similar business combinations with one or more target businesses, primarily in the healthcare, technology, green economy, and consumer products sectors across North America, Europe, and Asia. The company offers no current operational products or services beyond its SPAC structure, including units (MAAQU), common stock (MAAQ), warrants (MAAQW), and rights (MAAQR), which commenced trading on Nasdaq following its initial public offering priced at $10.00 per unit in November 2021, raising gross proceeds of $62 million. Incorporated in 2021 as a Delaware corporation, Mana Capital Acquisition Corp. maintains its headquarters at 8 The Green, Suite 12490, Dover, Delaware. In its major recent development, the company completed a reverse merger business combination with Cardio Diagnostics, Inc. on October 25, 2022, resulting in Mana being renamed Cardio Diagnostics Holdings, Inc., with its common stock and warrants transitioning to new tickers CDIO and CDIOW while legacy warrants (MAAQW) continue trading separately at a $11.50 exercise price; the combined entity, now a biotechnology firm developing AI-driven genetic-epigenetic tests for cardiovascular disease prevention and early detection such as Epi+Gen CHD, remains listed on Nasdaq. No further acquisitions, funding rounds, partnerships, or operational expansions have been reported for Mana Capital Acquisition Corp. itself since the merger, with MAAQW warrants reflecting post-transaction legacy securities amid ongoing trading activity into 2025.